Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer

A tissue microarray and digital imaging analysis-based study of 428 cases

Antoun Toubaji, Siobhan Sutcliffe, Alcides Chaux, Kristen Lecksell, Jessica Hicks, Angelo Michael Demarzo, Elizabeth A Platz, George J. Netto

Research output: Contribution to journalArticle

Abstract

Prostate cancer remains a major health problem in the United States. Established clinicopathologic parameters such as Gleason score, T stage, and prostate-specific antigen levels are currently the guiding tools for prognostication and disease management. The addition of biomarkers could increase the accuracy of these parameters for predicting disease progression, response to therapy, and survival. In this regard, the goal of this study was to evaluate minichromosome maintenance complex protein 2 and Ki-67 immunohistochemical expression as predictors of outcome in prostate cancer. For this purpose, 11 tissue microarrays were constructed using tumor and nontumor samples from 428 patients. Patients were divided into short-term (mean, 2.9 years) and long-term (mean, 14.1 years) follow-up groups. End points were biochemical recurrence for the short-term follow-up group and prostate cancer-related death for the long-term follow-up group. All men in the long-term follow-up group had biochemical recurrence at the time of recruitment. Expression of both markers was higher in tumor than in nontumor glands. Percentage of minichromosome maintenance complex protein 2 was associated with Gleason score in both groups. Percentage of Ki-67 was associated with Gleason score and pathologic stage only in the short-term follow-up group. Higher minichromosome maintenance complex protein 2 percentages were associated with biochemical recurrence in the short-term follow-up group. In the long-term follow-up group, neither minichromosome maintenance complex protein 2 nor Ki-67 levels predicted prostate cancer death. In conclusion, our results suggest that in patients treated by radical prostatectomy for clinically localized prostate cancer, immunohistochemistry for minichromosome maintenance complex protein 2 expression could be used to predict biochemical recurrence, independent of other known clinicopathologic factors.

Original languageEnglish (US)
Pages (from-to)1852-1865
Number of pages14
JournalHuman Pathology
Volume43
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Minichromosome Maintenance Proteins
Prostatic Neoplasms
Neoplasm Grading
Recurrence
Prostate-Specific Antigen
Prostatectomy
Disease Management
Disease Progression
Neoplasms
Biomarkers
Immunohistochemistry
Survival
Health

Keywords

  • Biochemical recurrence
  • Cancer-specific death
  • Ki-67
  • MCM2
  • Prostate cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer : A tissue microarray and digital imaging analysis-based study of 428 cases. / Toubaji, Antoun; Sutcliffe, Siobhan; Chaux, Alcides; Lecksell, Kristen; Hicks, Jessica; Demarzo, Angelo Michael; Platz, Elizabeth A; Netto, George J.

In: Human Pathology, Vol. 43, No. 11, 11.2012, p. 1852-1865.

Research output: Contribution to journalArticle

@article{79c6d77a6021465496ff1196ba32043b,
title = "Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer: A tissue microarray and digital imaging analysis-based study of 428 cases",
abstract = "Prostate cancer remains a major health problem in the United States. Established clinicopathologic parameters such as Gleason score, T stage, and prostate-specific antigen levels are currently the guiding tools for prognostication and disease management. The addition of biomarkers could increase the accuracy of these parameters for predicting disease progression, response to therapy, and survival. In this regard, the goal of this study was to evaluate minichromosome maintenance complex protein 2 and Ki-67 immunohistochemical expression as predictors of outcome in prostate cancer. For this purpose, 11 tissue microarrays were constructed using tumor and nontumor samples from 428 patients. Patients were divided into short-term (mean, 2.9 years) and long-term (mean, 14.1 years) follow-up groups. End points were biochemical recurrence for the short-term follow-up group and prostate cancer-related death for the long-term follow-up group. All men in the long-term follow-up group had biochemical recurrence at the time of recruitment. Expression of both markers was higher in tumor than in nontumor glands. Percentage of minichromosome maintenance complex protein 2 was associated with Gleason score in both groups. Percentage of Ki-67 was associated with Gleason score and pathologic stage only in the short-term follow-up group. Higher minichromosome maintenance complex protein 2 percentages were associated with biochemical recurrence in the short-term follow-up group. In the long-term follow-up group, neither minichromosome maintenance complex protein 2 nor Ki-67 levels predicted prostate cancer death. In conclusion, our results suggest that in patients treated by radical prostatectomy for clinically localized prostate cancer, immunohistochemistry for minichromosome maintenance complex protein 2 expression could be used to predict biochemical recurrence, independent of other known clinicopathologic factors.",
keywords = "Biochemical recurrence, Cancer-specific death, Ki-67, MCM2, Prostate cancer",
author = "Antoun Toubaji and Siobhan Sutcliffe and Alcides Chaux and Kristen Lecksell and Jessica Hicks and Demarzo, {Angelo Michael} and Platz, {Elizabeth A} and Netto, {George J.}",
year = "2012",
month = "11",
doi = "10.1016/j.humpath.2012.01.007",
language = "English (US)",
volume = "43",
pages = "1852--1865",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "11",

}

TY - JOUR

T1 - Immunohistochemical expression of minichromosome maintenance complex protein 2 predicts biochemical recurrence in prostate cancer

T2 - A tissue microarray and digital imaging analysis-based study of 428 cases

AU - Toubaji, Antoun

AU - Sutcliffe, Siobhan

AU - Chaux, Alcides

AU - Lecksell, Kristen

AU - Hicks, Jessica

AU - Demarzo, Angelo Michael

AU - Platz, Elizabeth A

AU - Netto, George J.

PY - 2012/11

Y1 - 2012/11

N2 - Prostate cancer remains a major health problem in the United States. Established clinicopathologic parameters such as Gleason score, T stage, and prostate-specific antigen levels are currently the guiding tools for prognostication and disease management. The addition of biomarkers could increase the accuracy of these parameters for predicting disease progression, response to therapy, and survival. In this regard, the goal of this study was to evaluate minichromosome maintenance complex protein 2 and Ki-67 immunohistochemical expression as predictors of outcome in prostate cancer. For this purpose, 11 tissue microarrays were constructed using tumor and nontumor samples from 428 patients. Patients were divided into short-term (mean, 2.9 years) and long-term (mean, 14.1 years) follow-up groups. End points were biochemical recurrence for the short-term follow-up group and prostate cancer-related death for the long-term follow-up group. All men in the long-term follow-up group had biochemical recurrence at the time of recruitment. Expression of both markers was higher in tumor than in nontumor glands. Percentage of minichromosome maintenance complex protein 2 was associated with Gleason score in both groups. Percentage of Ki-67 was associated with Gleason score and pathologic stage only in the short-term follow-up group. Higher minichromosome maintenance complex protein 2 percentages were associated with biochemical recurrence in the short-term follow-up group. In the long-term follow-up group, neither minichromosome maintenance complex protein 2 nor Ki-67 levels predicted prostate cancer death. In conclusion, our results suggest that in patients treated by radical prostatectomy for clinically localized prostate cancer, immunohistochemistry for minichromosome maintenance complex protein 2 expression could be used to predict biochemical recurrence, independent of other known clinicopathologic factors.

AB - Prostate cancer remains a major health problem in the United States. Established clinicopathologic parameters such as Gleason score, T stage, and prostate-specific antigen levels are currently the guiding tools for prognostication and disease management. The addition of biomarkers could increase the accuracy of these parameters for predicting disease progression, response to therapy, and survival. In this regard, the goal of this study was to evaluate minichromosome maintenance complex protein 2 and Ki-67 immunohistochemical expression as predictors of outcome in prostate cancer. For this purpose, 11 tissue microarrays were constructed using tumor and nontumor samples from 428 patients. Patients were divided into short-term (mean, 2.9 years) and long-term (mean, 14.1 years) follow-up groups. End points were biochemical recurrence for the short-term follow-up group and prostate cancer-related death for the long-term follow-up group. All men in the long-term follow-up group had biochemical recurrence at the time of recruitment. Expression of both markers was higher in tumor than in nontumor glands. Percentage of minichromosome maintenance complex protein 2 was associated with Gleason score in both groups. Percentage of Ki-67 was associated with Gleason score and pathologic stage only in the short-term follow-up group. Higher minichromosome maintenance complex protein 2 percentages were associated with biochemical recurrence in the short-term follow-up group. In the long-term follow-up group, neither minichromosome maintenance complex protein 2 nor Ki-67 levels predicted prostate cancer death. In conclusion, our results suggest that in patients treated by radical prostatectomy for clinically localized prostate cancer, immunohistochemistry for minichromosome maintenance complex protein 2 expression could be used to predict biochemical recurrence, independent of other known clinicopathologic factors.

KW - Biochemical recurrence

KW - Cancer-specific death

KW - Ki-67

KW - MCM2

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84867868561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867868561&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2012.01.007

DO - 10.1016/j.humpath.2012.01.007

M3 - Article

VL - 43

SP - 1852

EP - 1865

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 11

ER -